NCT04544891

TREM-1 Pathway Activation in COVID-19

Prognostic Significance of the TREM-1 Pathway Activation in COVID-19

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 830 (actual)
• Sponsor: Central Hospital, Nancy, France · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: —

Summary

Severe Acute Respiratory Syndrome-Corona Virus-2 infection results in a mild infection in most of the patients. However, 15-20% require hospitalization, and among them, 15-20% will develop acute respiratory failure, leading to their admission in Intensive Care Unit. There are no accepted predictive criteria for aggravation. Severe forms of Coronavirus induced disease-19 (COVID-19) are the consequence of endotheliopathy, and hyperinflammatory and pro-coagulant state. The Triggering Receptor Expressed on Myeloid cells-1 (TREM-1) is an immunoreceptor that acts as an amplifier of the inflammatory response. TREM-1 is expressed on myeloid and endothelial cells. Its activation leads to endothelial activation and damage, hyperinflammatory, and pro-coagulant state. TREM-1 activation is associated with poor outcome during septic shock and myocardial infarction. We here aim at investigating the relationship between TREM-1 pathway activation and clinical degradation and outcome of COVID-19 hospitalized patients.

Conditions

• Covid19

Interventions

Type	Name	Description
OTHER	blood sampling	Blood will be collected every 3 days until Day 28, discharge, or death

Timeline

• Start date: 2020-10-01
• Primary completion: 2022-03-01
• Completion: 2022-03-01
• First posted: 2020-09-10
• Last updated: 2022-03-22

Locations

2 sites across 1 country: France